Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

December 9, 2003

Slides

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Ranexa™ (ranolazine) Extended Release Tablets - Introduction, Dr. Michael Sweeney, MD FRCP, CV Therapeutics, Inc.(HTM) (PPT)

Ranexa® for Chronic Angina - An Unmet Need, Dr. Eugene Braunwald, MD, FACC, Harvard Medical School (HTM) (PPT)

Clinical Evaluation of Ranolazine Efficacy and Safety, Dr. Andrew Wolff, MD FACC, CV Therapeutics, Inc. (HTM) (PPT)

Surrogate Markers of Pro-Arrhythmic Risk, Dr. Peter Kowey, MD FACC, Mainline Heart Health Center (HTM) (PPT)

Mechanistic Evaluation of the Effects of Ranolazine on Ventricular Repolarization, Dr. Luiz Belardinelli, MD, CV Therapeutics, Inc. (HTM) (PPT)

Cllinical Evaluation of the Effects of Ranolazine on Ventricular Repolarization, Dr. Andrew Wolff, MD, FACC, CV Therapeutics, Inc. (HTM) (PPT)

Ranolazine Benefit/Risk, Dr. Jeremy Ruskin, MD, FACC, CV Therapeutics, Inc. (HTM) (PPT)

Ranexa™ Supportive Slides, CV Therapeutics, Inc. (HTM) (PPT)